

LEXICON PHARMACEUTICALS, INC.

Form SC 13G/A

January 20, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)

LEXICON PHARMACEUTICALS, INC.

(Name of Issuer)

-----  
Common Stock

(Title of Class of Securities)  
-----

528872302

(CUSIP Number)  
-----

December 31, 2016

Date of Event Which Requires Filing of this Statement)  
-----

Check the appropriate box to designate the rule pursuant to  
which this Schedule is filed:

/x/ Rule 13d-1(b)

/ / Rule 13d-1(c)

/ / Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a  
reporting person's initial filing on this form with respect  
to the subject class of securities, and for any subsequent  
amendment containing information which would alter the  
disclosures provided in a prior cover page.

The information required in the remainder of this cover  
page shall not be deemed to be "filed" for the purpose of  
Section 18 of the Securities Exchange Act of 1934 ("Act")  
or otherwise subject to the liabilities of that section  
of the Act but shall be subject to all other provisions  
of the Act (however, see the Notes).

Potential persons who are to respond to the collection of  
information contained in this form are not required to  
respond unless the form displays a currently valid OMB  
control number.

1. Names of Reporting Persons and I.R.S. Identification No.

UBS Group AG (for the benefit and on behalf of the UBS  
Asset Management division of UBS Group AG, see Item 7)

98-0186363

Edgar Filing: LEXICON PHARMACEUTICALS, INC. - Form SC 13G/A

-----  
2. Check the Appropriate Box if a Member of a Group

a    /    /

b    /    /    See Item 8 of attached schedule  
-----

3. SEC USE ONLY  
-----

4. Citizenship or Place of Organization

Switzerland  
-----

|               |                             |            |
|---------------|-----------------------------|------------|
| Number of     | 5. Sole Voting Power        | 4,977,180* |
| Shares Bene-  | 6. Shared Voting Power      | 0          |
| ficially      | 7. Sole Dispositive Power   | 0          |
| Owned by Each | 8. Shared Dispositive Power | 5,224,214* |

Reporting  
Person With:  
-----

9. Aggregate Amount Beneficially Owned by Each Reporting Person:

5,224,214\*  
-----

10. Check if the Aggregate Amount in Row 9 Excludes Certain  
Shares    /    /  
-----

11. Percent of Class Represented by Amount in Row 9

5.02%  
-----

12. Type of Reporting Person

HC  
-----

\*The Reporting Person disclaims beneficial ownership of such securities pursuant to Rule 13d-4 under the Securities Exchange Act of 1934. In accordance with SEC Release No. 34-39538 (January 12, 1998), this filing reflects the securities beneficially owned by the UBS Asset Management division of UBS Group AG and its subsidiaries and affiliates on behalf of its clients. This filing does not reflect securities, if any, beneficially owned by any other division of UBS Group AG.  
-----

Cusip 528872302  
-----

Item 1(a). Name of Issuer:

# Edgar Filing: LEXICON PHARMACEUTICALS, INC. - Form SC 13G/A

LEXICON PHARMACEUTICALS, INC.

Item 1(b). Address of Issuer's Principal Executive Offices:

8800 TECHNOLOGY FOREST PLACE  
THE WOODLANDS, TX 77381

-----  
Item 2(a) Name of Persons Filing:

UBS Group AG

Item 2(b) Address of Principal Business Office or, if none,  
Residence:

UBS Group AG's principal business office is:  
Bahnhofstrasse 45  
Zurich, Switzerland

Item 2(c) Citizenship:

Incorporated by reference to Item 4 of the cover pages.

Item 2(d) Title of Class of Securities:

Common Stock (the "Common Stock")

Item 2(e) CUSIP Number:

528872302

-----  
Item 3. Type of Person Filing:

If this statement is filed pursuant to Rules 13d-1(b), or  
13d-2(b) or (c), check whether the person filing is a:

/ / Broker or dealer registered under Section 15 of the Act;  
/ / Bank as defined in Section 3(a)(6) of the Act;  
/ / Insurance company as defined in Section 3(a)(19) of the Act;  
/ / Investment company registered under Section 8 of the  
Investment Company Act of 1940;  
/ / An investment adviser in accordance with Rule 13d-1(b)(1)  
(ii)(E);  
/ / An employee benefit plan or endowment fund in accordance  
with Rule 13d-1(b)(1)(ii)(F);  
/X/ A parent holding company or control person in accordance  
with Rule 13d-1(b)(1)(ii)(G);  
/ / A savings association as defined in Section 3(b) of the  
Federal Deposit Insurance Act (12 U.S.C. 1813);  
/ / A church plan that is excluded from the definition of an  
investment company under Section 3(c)(14) of the  
Investment Company Act of 1940;  
/ / A non-U.S. institution in accordance with Rule 240.13d-1  
(b)(1)(ii)(J);  
/ / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).  
If filing as a non-U.S. institution in accordance with  
Rule 240.13d-1(b)(1)(ii)(J), please specify the type of  
institution.

-----  
Item 4 (a)-(c)(iv). Ownership:

## Edgar Filing: LEXICON PHARMACEUTICALS, INC. - Form SC 13G/A

Incorporated by reference to Items 5-11 of the cover pages.

The amount of shares beneficially owned includes shares of common stock (CUSIP 528872302) issuable upon conversion of 5.25% convertible notes due 2021 (CUSIP 528872AB0).

-----  
Cusip 528872302  
-----

### Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following / /.

### Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Accounts managed on a discretionary basis by the UBS Asset Management division of UBS Group AG (UBS AM) have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities. To the best of our knowledge, no account holds more than 5 percent of the outstanding Securities being reported in this filing.

### Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

Identification: UBS Asset Management (Americas) Inc.  
Classification: IA

In addition to UBS Group AG, the following UBS AM affiliates and subsidiaries are part of the UBS Asset Management division included in this filing: UBS AG, UBS Asset Management (Americas) Inc., UBS Asset Management Trust Company, UBS Asset Management (Canada) Inc., UBS Asset Management (Australia) Ltd., UBS Asset Management (Hong Kong) Limited, UBS Asset Management (Japan) Ltd., UBS Asset Management (Singapore) Ltd., UBS Asset Management (Taiwan) Ltd., UBS Asset Management (Deutschland) GmbH, UBS Asset Management (Italia) SGR SpA, UBS Asset Management (UK) Ltd., UBS Asset Management Life Limited, and UBS Hana Asset Management Co., Ltd., and UBS Asset Management France SA.

UBS Group AG acquired UBS AG through the completion of a share transfer offer on 28 November 2014 in which the shareholders of UBS AG became shareholders of UBS Group AG and their shares in UBS AG were transferred to UBS Group AG. As a result, UBS Group AG controls UBS AG.

### Item 8

UBS AM is composed of wholly-owned subsidiaries and branches of UBS Group AG. UBS Group AG is reporting direct and indirect beneficial ownership of holdings. None of the

Edgar Filing: LEXICON PHARMACEUTICALS, INC. - Form SC 13G/A

reporting persons affirm the existence of a group within the meaning of Rule 13d-5(b)(1).

Cusip 528872302

Item 9 Notice of Dissolution of Group:  
Not Applicable

Item 10 Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 1, 2017

UBS Group AG

By: /s/ Mark F. Kemper  
Mark F. Kemper  
Attorney-in-Fact  
pursuant to Power of Attorney, attached as Exhibit 1,  
for the UBS Asset Management division  
of UBS Group AG

By: /s/ Michael J. Calhoun  
Michael J. Calhoun  
Attorney-in-Fact  
pursuant to Power of Attorney, attached as Exhibit 1,  
for the UBS Asset Management division  
of UBS Group AG

EXHIBIT INDEX

| Exhibit Number | Exhibit Description                               |
|----------------|---------------------------------------------------|
| 1              | Power of Attorney<br>dated as of January 12, 2015 |

# Edgar Filing: LEXICON PHARMACEUTICALS, INC. - Form SC 13G/A

## EXHIBIT 1

### POWER OF ATTORNEY

Each of the following representatives of UBS Global Asset Management (Americas) Inc. is hereby appointed as agent and attorney-in-fact with power and authority to sign US Regulatory Filings, including Schedule 13G and Form 13F, on behalf of UBS Group AG and its affiliates in the UBS Global Asset Management division:

Joseph Allessie  
James Barling  
Michael J. Calhoun  
Mark F. Kemper  
John Moore  
Barry Mullen  
Jennifer Wiley

All prior powers of attorney relating to the subject matter of this Power of Attorney are hereby revoked. This Power of Attorney is limited to the circumstances set forth herein and may be revoked, in whole or in part, at any time. If a person identified above ceases to perform services for UBS Global Asset Management for any reason, this Power of Attorney shall be automatically revoked with respect to that person. Nothing in this Power of Attorney is intended to limit the authority of any other persons to sign documents relating to the subject matter hereof to the extent permitted by UBS Group Policy or otherwise.

APPROVED:

Date: As of January 12, 2015

/s/ Mario Cueni  
Mario Cueni  
UBS Global Asset Management  
General Counsel  
Group Managing Director

/s/ Shawn Lytle  
Shawn Lytle  
UBS Global Asset Management  
Head of Americas  
Group Managing Director